WO2006126081A3 - Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors - Google Patents

Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors Download PDF

Info

Publication number
WO2006126081A3
WO2006126081A3 PCT/IB2006/001386 IB2006001386W WO2006126081A3 WO 2006126081 A3 WO2006126081 A3 WO 2006126081A3 IB 2006001386 W IB2006001386 W IB 2006001386W WO 2006126081 A3 WO2006126081 A3 WO 2006126081A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyrazinones
pyridino
pde
inhibitors
methods
Prior art date
Application number
PCT/IB2006/001386
Other languages
French (fr)
Other versions
WO2006126081A2 (en
Inventor
Andrew Simon Bell
Alan George Benson
David Graham Brown
David Louis Brown
Yvette Marlene Fobian
John Nicholas Freskos
Steven Edward Heasley
Robert Owen Hughes
Eric Jon Jacobsen
Brent Virgil Mischke
John Major Molyneaux
Joseph Blair Moon
Dafydd Rhys Owen
Michael John Palmer
Christopher Phillips
Donald Joseph Rogier Jr
John Keith Walker
Todd Michael Maddux
Michael Brent Tollefson
Original Assignee
Pharmacia & Upjohn Co Llc
Andrew Simon Bell
Alan George Benson
David Graham Brown
David Louis Brown
Yvette Marlene Fobian
John Nicholas Freskos
Steven Edward Heasley
Robert Owen Hughes
Eric Jon Jacobsen
Brent Virgil Mischke
John Major Molyneaux
Joseph Blair Moon
Dafydd Rhys Owen
Michael John Palmer
Christopher Phillips
Donald Joseph Rogier Jr
John Keith Walker
Todd Michael Maddux
Michael Brent Tollefson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc, Andrew Simon Bell, Alan George Benson, David Graham Brown, David Louis Brown, Yvette Marlene Fobian, John Nicholas Freskos, Steven Edward Heasley, Robert Owen Hughes, Eric Jon Jacobsen, Brent Virgil Mischke, John Major Molyneaux, Joseph Blair Moon, Dafydd Rhys Owen, Michael John Palmer, Christopher Phillips, Donald Joseph Rogier Jr, John Keith Walker, Todd Michael Maddux, Michael Brent Tollefson filed Critical Pharmacia & Upjohn Co Llc
Priority to CA002603830A priority Critical patent/CA2603830A1/en
Publication of WO2006126081A2 publication Critical patent/WO2006126081A2/en
Publication of WO2006126081A3 publication Critical patent/WO2006126081A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compounds of Formula (I), wherein R2, Y6, R6A, R6, and R8 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, synthetic methods, and intermediates are also disclosed.
PCT/IB2006/001386 2005-05-24 2006-05-17 Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors WO2006126081A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002603830A CA2603830A1 (en) 2005-05-24 2006-05-17 Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68413005P 2005-05-24 2005-05-24
US60/684,130 2005-05-24

Publications (2)

Publication Number Publication Date
WO2006126081A2 WO2006126081A2 (en) 2006-11-30
WO2006126081A3 true WO2006126081A3 (en) 2007-01-18

Family

ID=37046762

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/001386 WO2006126081A2 (en) 2005-05-24 2006-05-17 Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors

Country Status (2)

Country Link
CA (1) CA2603830A1 (en)
WO (1) WO2006126081A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009011387A (en) * 2007-05-12 2009-11-09 Bayer Schering Pharma Ag sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS.
AU2009221213B2 (en) 2008-03-05 2014-02-27 Merck Patent Gmbh Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
EP2308877B1 (en) 2008-08-05 2014-01-22 Daiichi Sankyo Company, Limited Imidazopyridin-2-one derivatives
CN101747282A (en) 2008-12-10 2010-06-23 上海特化医药科技有限公司 Phenyl pyrimidone compounds, pharmaceutical compositions and preparation methods and uses thereof
JP5767393B2 (en) 2011-03-31 2015-08-19 ファイザー・インク New bicyclic pyridinone
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
WO2013030713A1 (en) 2011-08-31 2013-03-07 Pfizer Inc. Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds
CA2872154C (en) 2012-05-04 2016-08-23 Pfizer Inc. Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds as inhibitors of app, bace1 and bace2
CA2882389A1 (en) 2012-09-20 2014-03-27 Pfizer Inc. Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
UA110688C2 (en) 2012-09-21 2016-01-25 Пфайзер Інк. Bicyclic pirydynony
JP2016502978A (en) 2012-12-11 2016-02-01 ファイザー・インク Hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds as inhibitors of BACE1
JP6162820B2 (en) 2012-12-19 2017-07-12 ファイザー・インク Carbocyclic and heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds
WO2014125394A1 (en) 2013-02-13 2014-08-21 Pfizer Inc. HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2014128585A1 (en) 2013-02-19 2014-08-28 Pfizer Inc. Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders
WO2015049616A1 (en) 2013-10-04 2015-04-09 Pfizer Inc. Novel bicyclic pyridinones as gamma-secretase modulators
AU2015242330B2 (en) 2014-04-01 2017-08-17 Pfizer Inc. Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
MD20160105A2 (en) 2014-04-10 2017-03-31 Pfizer Inc. 2-Amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
EP3177624B1 (en) 2014-08-06 2019-05-01 Pfizer Inc Imidazopyridazine compounds
WO2016125048A1 (en) 2015-02-03 2016-08-11 Pfizer Inc. Novel cyclopropabenzofuranyl pyridopyrazinediones
CA2989456C (en) 2015-06-17 2022-01-04 Pfizer Inc. Tricyclic compounds and their use as phosphodiesterase inhibitors
JP2018531924A (en) 2015-09-24 2018-11-01 ファイザー・インク Tetrahydropyrano [3,4-D] [1,3] oxazine derivatives and their use as BACE inhibitors
WO2017051294A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors
JP2018531923A (en) 2015-09-24 2018-11-01 ファイザー・インク N- [2- (2-Amino-6,6-disubstituted-4,4a, 5,6-tetrahydropyrano [3,4-d] [1,3] thiazin-8a (8H) -yl)- 1,3-thiazol-4-yl] amide
CN113332292A (en) 2016-02-23 2021-09-03 辉瑞公司 6, 7-dihydro-5H-pyrazolo [5,1-b ] [1,3] oxazine-2-carboxamide compounds
JP7046018B2 (en) 2016-07-01 2022-04-01 ファイザー・インク 5,7-Dihydropyrrolopyridine derivative for treating neurological and neurodegenerative diseases
US11198692B2 (en) 2017-06-22 2021-12-14 Pfizer Inc. Dihydro-pyrrolo-pyridine derivatives
CN109400463B (en) * 2017-08-16 2021-10-22 北京颖泰嘉和生物科技股份有限公司 Preparation method of 2-n-propoxyacetyl chloride
FI3768669T3 (en) 2018-03-23 2023-04-26 Pfizer Piperazine azaspiro derivaves
BR112021013924A2 (en) 2019-01-18 2021-09-21 Astrazeneca Ab PCSK9 INHIBITORS AND METHODS OF USING THEM
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996001825A1 (en) * 1994-07-11 1996-01-25 Fujisawa Pharmaceutical Co., Ltd. Heterobicyclic derivatives
WO1997024355A1 (en) * 1995-12-27 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Pyrido (2,3-b) pyrazine derivatives
US20020147199A1 (en) * 2000-03-14 2002-10-10 Degenhard Marx Process for the treatment of erectile dysfunction and product therefor
EP1364950A1 (en) * 2001-02-26 2003-11-26 Tanabe Seiyaku Co., Ltd. Pyridopyrimidine or naphthyridine derivative

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996001825A1 (en) * 1994-07-11 1996-01-25 Fujisawa Pharmaceutical Co., Ltd. Heterobicyclic derivatives
WO1997024355A1 (en) * 1995-12-27 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Pyrido (2,3-b) pyrazine derivatives
US20020147199A1 (en) * 2000-03-14 2002-10-10 Degenhard Marx Process for the treatment of erectile dysfunction and product therefor
EP1364950A1 (en) * 2001-02-26 2003-11-26 Tanabe Seiyaku Co., Ltd. Pyridopyrimidine or naphthyridine derivative

Also Published As

Publication number Publication date
CA2603830A1 (en) 2006-11-30
WO2006126081A2 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
WO2006126081A3 (en) Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors
WO2006126082A3 (en) Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
MY148583A (en) Pyridine [3,4-b] pyrazinones
WO2005037198A3 (en) Preparation of 1,7-disubstituted azabenzimidazoles as kinase inhibitors
IL185611A0 (en) Novel imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same
WO2007028135A3 (en) Imidazopyridine compounds
WO2007058850A3 (en) Inhibitors of akt activity
EP1814885A4 (en) Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them
WO2005037197A3 (en) Preperation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors
HK1093503A1 (en) Pyrido 2, 1-a-isoquinoline derivatives as ddp-IV inhibitors
WO2006032342A3 (en) Carbonyl compound-containing drug and the use thereof
WO2006034039A3 (en) Substituted morphinans and methods of their use
WO2007023110A3 (en) P38 map kinase inhibitors and methods for using the same
IL175813A0 (en) PYRIDO [2,3-d] PYRIMIDINE-2,4-DIAMINES AS PDE 2 INHIBITORS
WO2005118540A3 (en) Bicyclic, nitrogen-containing heterocycles as aromatase inhibitors
WO2007061923A3 (en) Glucokinase activators
EP1670466A4 (en) Preparation of 1, 6, 7- trisubstituted azabenzimidazoles as kinase inhibitors
WO2005021544A3 (en) N3-substituted imidazopyridine-derivatives as c-kit inhibitors
WO2006005726A3 (en) Heterocyclic compounds
IL182963A0 (en) Imidazo[1,2-a] pyridine compounds, compositions, uses and methods related thereto
WO2006113837A3 (en) Inhibitors of akt activity
WO2006125555A3 (en) Quinazolinones
AU2006321904A8 (en) 1, 1, 3-trioxo-1 , 2 , 5-thiadiazolidines and their use as PTP-ases inhibitors
WO2008027600A3 (en) Imatinib compositions
WO2007147103A3 (en) Novel compounds

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2603830

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06744777

Country of ref document: EP

Kind code of ref document: A2